Form 4: Bio-Rad Laboratories CFO Robin Harper Cowie Acquires 62,358 Stock Options
SEC Form 4 Filing
Robin Harper Cowie, CFO, Sec'y & Treasurer of BIODESIX INC, acquired 62,358 stock options on February 21, 2024, as part of the company's 2023 Bonus-to-Options Program.
Summary
- Robin Harper Cowie, the CFO, Secretary, and Treasurer of BIODESIX INC, filed a Form 4 on February 29, 2024, reporting a transaction.
- On February 21, 2024, Cowie acquired 62,358 stock options with an exercise price of $1.46.
- These options vested fully on the grant date and expire on February 20, 2034.
- The acquisition was part of the Issuer's 2023 Bonus-to-Options Program, where Cowie elected to receive a portion of the annual cash bonus in the form of fully-vested options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction related to executive compensation. The acquisition of stock options by an executive is generally viewed as a positive sign, but it's not a major event.
Positives
- The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.
Management Comments
- Under the Issuer's 2023 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2023 in the form of a fully-vested option.
Industry Context
This type of stock option grant is a common practice in the industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology and diagnostics industries.
- Companies like Exact Sciences and Guardant Health also utilize stock options as part of their executive compensation plans.
- The size and vesting schedule of these grants are typically benchmarked against peer companies to ensure competitiveness.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment due to the alignment of executive interests with shareholder value.
Key Dates
| Date | Description |
|---|---|
| 02/21/2024 | Date of stock options transaction and vesting. |
| 02/20/2034 | Expiration date of the stock options. |
| 02/29/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.